While Prgoenza and its applications are currently at front and centre, RGS is also conducting a phase 1 autologuus cancer vaccine trial for RGS H4K, which they hope to finish recruitment for in the next 12 months. In addition I note that RGS has commenced a pre-clinical study looking at a combo therapy of RGSH4K and pd-1. (Source: Annual Report p.4). It will be very interesting to see the results of these.
Ann: FY17 Results Presentation, page-3
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
